Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerance of different dose levels

Outcome Time Frame:

12 weeks

Safety Issue:

Yes

Principal Investigator

William Wegener, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Immunomedics, Inc.

Authority:

United States: Food and Drug Administration

Study ID:

IM-T-hA20-01

NCT ID:

NCT00285428

Start Date:

September 2004

Completion Date:

October 2007

Related Keywords:

• Non-Hodgkin's Lymphoma
• treatment
• NHL
• CD20+ B-cell NHL
• Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin

Name	Location
MD Anderson Cancer Center	Houston, Texas  77030-4096
New York Presbyterian Hospital/Cornell Medical Center	New York, New York  10021
University Hospital of Pennsylvania	Philadelphia, Pennsylvania  19104